|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,659.00 INR | +1.03% |
|
+0.95% | +2.77% |
| 02/06 | Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 | CI |
| 02/06 | Alkem Laboratories Shows Strong Moves But Weak Follow-Through |  |
| Market Cap | 68TCr 703.1Cr 614.72Cr 567.07Cr 521.28Cr 987.7Cr 1TCr 6.77TCr 2.66TCr 33TCr 2.64TCr 2.58TCr 1,14000Cr | P/E 2026 |
27.5x | P/E 2027 * | 29x |
|---|---|---|---|---|---|
| Enterprise Value | 65TCr 673.86Cr 589.16Cr 543.49Cr 499.6Cr 946.63Cr 962.81Cr 6.49TCr 2.55TCr 32TCr 2.53TCr 2.48TCr 1,09200Cr | EV / Sales 2026 |
4.3x | EV / Sales 2027 * | 3.96x |
| Free-Float |
37.56% | Yield 2026 |
1% | Yield 2027 * | 0.91% |
Last Transcript: Alkem Laboratories Limited
| 1 day | +1.03% | ||
| 1 week | +0.95% | ||
| Current month | +1.60% | ||
| 1 month | +6.09% | ||
| 3 months | +1.50% | ||
| 6 months | -2.94% | ||
| Current year | +2.77% |
| 1 week | 5,515.5 |  | 5,727.5 |
| 1 month | 5,321 | | 5,735 |
| Current year | 5,075 | | 5,933.5 |
| 1 year | 4,738.5 | | 5,933.5 |
| 3 years | 3,447 | | 6,439.9 |
| 5 years | 2,828 | | 6,439.9 |
| 10 years | 1,400.6 | | 6,439.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rajorshi Ganguli
PSD | President | - | - |
Akhilesh Sharma
PSD | President | - | - |
Nitin Agrawal
DFI | Director of Finance/CFO | - | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Sandeep Singh
BRD | Director/Board Member | 44 | 09/08/2013 |
| Director/Board Member | 63 | 11/02/2008 | |
Sarvesh Singh
BRD | Director/Board Member | 44 | 11/11/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.03% | +0.95% | +14.71% | +60.80% | 697.17Cr | |
| +0.35% | -4.87% | +49.87% | +157.34% | 1,02800Cr | |
| -2.69% | -6.22% | +59.19% | +54.51% | 61TCr | |
| +0.44% | -3.41% | +30.97% | +79.48% | 43TCr | |
| +0.98% | -1.40% | +29.49% | +21.76% | 32TCr | |
| -0.34% | -3.10% | +27.00% | +43.60% | 28TCr | |
| +1.63% | -11.76% | +19.72% | +21.72% | 26TCr | |
| +3.39% | +2.29% | -23.68% | -37.83% | 22TCr | |
| +0.86% | -2.63% | +22.50% | +57.55% | 19TCr | |
| +1.28% | -3.03% | +20.76% | +70.62% | 16TCr | |
| Average | +0.69% | -4.26% | +25.05% | +52.95% | 35.05TCr | |
| Weighted average by Cap. | +0.19% | -4.84% | +35.81% | +76.67% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 15TCr 151.98Cr 132.88Cr 122.58Cr 112.68Cr 213.5Cr 217.15Cr 1.46TCr 574.19Cr 7.15TCr 570.75Cr 558.24Cr 25TCr | 17TCr 171.8Cr 150.2Cr 138.56Cr 127.37Cr 241.34Cr 245.46Cr 1.65TCr 649.05Cr 8.08TCr 645.17Cr 631.03Cr 28TCr |
| Net income | 2.51TCr 26Cr 23Cr 21Cr 19Cr 37Cr 37Cr 251.44Cr 99Cr 1.23TCr 98Cr 96Cr 4.23TCr | 2.36TCr 25Cr 21Cr 20Cr 18Cr 34Cr 35Cr 236.04Cr 93Cr 1.15TCr 92Cr 90Cr 3.97TCr |
| Net Debt | -2.81TCr -29Cr -26Cr -24Cr -22Cr -41Cr -42Cr -281.52Cr -110.46Cr -1.38TCr -109.8Cr -107.39Cr -4.74TCr | -2.17TCr -23Cr -20Cr -18Cr -17Cr -32Cr -32Cr -217.47Cr -85Cr -1.06TCr -85Cr -83Cr -3.66TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | ₹5,659.00 | +1.03% | 2,13,207 |
| 14/26/14 | ₹5,601.50 | +0.62% | 5,21,134 |
| 13/26/13 | ₹5,567.00 | -1.81% | 2,19,164 |
| 10/26/10 | ₹5,669.50 | +0.37% | 1,04,124 |
| 09/26/09 | ₹5,648.50 | +0.76% | 39,730 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALKEM Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
